First NK Cell Therapy Approval Expected By 2028 Says Kuick Research In Its New Research Study On Global NK Cell Therapy ...

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...

For cell and gene therapy, a consistent supply of quality starting material is vital that is maintained throughout the ...

A multi-institutional team led by The University of Osaka developed a chimeric antigen receptor (CAR) T cell-based strategy ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer cases. Immune checkpoint ...

The AdventHealth Neuroscience Institute is testing IDP-023 for primary or nonactive secondary progressive multiple sclerosis ...

NKGen Biotech's CEO will present Phase 1 clinical trial results for NK cell therapy in Alzheimer's at AD/PD™ 2025. NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at ...

The biotech is slashing a third of its workforce and more than half of its executive team in moves it called “necessary in ...

Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com . A webcast replay will be made available following the ...

About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...